Detalles de la búsqueda
1.
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
Am Heart J
; 231: 121-127, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33065120
2.
Legal and ethical framework for global health information and biospecimen exchange - an international perspective.
BMC Med Ethics
; 21(1): 8, 2020 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31964390
3.
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial.
J Cardiovasc Pharmacol Ther
; 27: 10742484221121507, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36282079
4.
Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
Trials
; 19(1): 581, 2018 Oct 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30352601
5.
Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
Trials
; 18(1): 333, 2017 07 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-28720112
6.
Propofol Use in the Elderly Population: Prevalence of Overdose and Association With 30-Day Mortality.
Clin Ther
; 37(12): 2676-85, 2015 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26548320
7.
Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013: A Cross-sectional Study.
JAMA Intern Med
; 176(4): 551-2, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26902933
Resultados
1 -
7
de 7
1
Próxima >
>>